Calgary, Alberta, March 17, 2022 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX: RVX) is today “BET Protein Inhibition for Pulmonary Arterial Hypertension: Pilot Clinical TrialsIs featured in the prestigious American Journal of Respiratory and Critical Care Medicine with an impact factor of 21.4. This article outlines the positive effects of apabetaron on APPRoAcH-p, a pilot study of investigator-led pulmonary arterial hypertension (PAH).
The article is here
“The promising results announced today highlight the potential benefits of BET protein inhibition, such as Resverlogix’s apabetaron, as a treatment strategy for PAH,” said Steve Pro, Director of Lung Research, Quebec Cardiopulmonary Research Institute, Laval University. Dr. Venture said. First author of the article. “We are excited to pursue a larger trial of apabetaron in patients with PAH.”
The highlights of the publication are:
- All patients completed the 16-week study without discontinuation or dose reduction. This suggests that apabetaron was well tolerated in the study population.
- Patients treated with apabetaron showed reduced pulmonary vascular resistance (PVR) at 16 weeks. This is the primary exploratory effectiveness endpoint of the study.
- Apavetalon treatment was also associated with improved cardiac output (CO) and stroke volume (SV) over a 16-week course of treatment.
“The APPRoAcH pilot study has shown the potential benefits that apabetaron can provide to patients with PAH,” said Donald J. McCaffrey, President and CEO of Resverlogix. “We are excited to work with Dr. Proventure of the Quebec Cardiopulmonary Institute and his colleagues to help bring this life-saving treatment to market, and the IUCPQ Foundation for this work. I would like to recognize the important contribution of. “
An introduction to the measurement of results used in this test can be found here.
Click here for an overview of the APPRoAc H-p trial design
The full test results will be announced at the next scientific conference (undecided). The promising results of this study paved the way for a larger multicenter APPRoAcH-2 trial, which is scheduled to begin patient enrollment later this year, PAH.
Apabetaron (RVX-208) is the first small molecule therapeutic candidate in its class with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extraterminal) inhibitor that helps prevent and treat disease progression by regulating the expression of the disease-causing genes.
The broad role of BET proteins in the human body allows apabetaron to simultaneously target multiple disease-related biological processes while maintaining a well-explained safety profile, a new treatment for chronic diseases. It leads to the method. Apavetalon has been designated as a breakthrough therapy by the US Food and Drug Administration (FDA) and is the only drug in its class with established safety records in human clinical trials, with 10 clinical trials. It is well over 4200 patient years.
COVID-19 (New Coronavirus Infection:
Following publication in Nature on March 23, 2020, written by a consortium of leading universities and research institutes, Resverlogix launched the COVID-19 program, conducting in-house research and recruiting world-renowned collaborators. I did. Studies published in well-known scientific journals (including Cell) show that apabetaron may act on COVID-19 by a unique dual mechanism. The second is to avoid excessive inflammatory reactions that can cause severe and persistent organ damage.
Phase 2b clinical trials are evaluating apabetaron in combination with standard of care for patients admitted with COVID-19. Clinical trial treatment may potentially reduce the severity and duration of COVID-19. The unique dual mechanism of apabetaron also means that it may be effective against new COVID-19 mutants and may also be useful in combating other viruses.
Resverlogix has partnered with EVERSANA ™, a pioneer of next-generation commercial services for the global life sciences industry, to support the rapid commercialization of COVID-19 apabetalon in Canada and the United States. EVERSANA ™ is currently a leader in clinical outreach and advocacy for Apabetaron in the Canadian market.
In February 2020, Apabetaron became the first treatment to receive breakthrough therapy designation from the US Food and Drug Administration (FDA) following the breakthrough discovery of the BETonMACE Phase 3 study. BETonMACE data show that apabetaron may prevent major cardiac adverse events in patients with high-risk cardiovascular disease who also suffer from type 2 diabetes.
Founded in 2001, Resverlogix is a Calgary-based late-stage biotechnology company with a global focus on epigenetics or gene regulation aimed at developing prestigious therapies for the benefit of patients with chronic diseases. I’m a leader.
Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of genes that cause disease. We aim to improve the lives of patients by restoring the biological functions altered by serious illnesses such as cardiovascular disease to a healthier state.
Our clinical program focuses on the assessment of apabetaron, a leading epigenetic candidate for the treatment of cardiovascular disease and related comorbidities, and COVID-19.
Common stock of Resverlogix is traded on the Toronto Stock Exchange (TSX: RVX).
Follow us: Twitter: @Resverlogix_RVX. LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/
About the Quebec Cardiopulmonary Research Institute – IUCPQ.qc.ca
Each year, 13,757 * were hospitalized and 115,654 outpatients visited 41,670 users. The service area is over 2 million people, which is about 30% of Quebec’s population. The institution, affiliated with Laval University, has more than 3,750 employees, doctors, specialists, researchers, managers, and to provide quality care and services to both inpatients and outpatients. We rely on the cooperation and dedication of our volunteers. In particular, the Institute offers specialized and ultra-professional care and service programs to treat cardiovascular and respiratory illnesses, as well as obesity-related illnesses. Our doctors and medical professionals have a wide range of specialized knowledge and contribute to the advancement of medicine. It is also our mission to evaluate health techniques and interventions. The institute’s research center is internationally recognized for its scientific quality.
* Financial data from 2020 to 2021
About the IUCPQ Foundation
The role of the IUCPQ Foundation is to promote and support the activities of IUCPQ-UL. The main mission of this activity is the health of individuals with cardiovascular, respiratory and obesity-related illnesses. The IUCPQ Foundation’s annual research competition allows many researchers to undertake and continue their work for the benefit of people and people with cardiovascular, respiratory, and obesity-related illnesses.
In recent years, the Foundation has donated nearly $ 40 million by funding the purchase of specialized equipment and funding research and education. This has contributed to the greater benefits of the population of central and eastern Quebec, which accounts for more than 2.2 million people. ..
About the research center
The research center’s vision is to play an internationally important role in the fight against chronic social illness through integrated science models in cardiology, respiratory science, and obesity-type 2 diabetes metabolism. It relies on the cooperation of 177 researchers and physician scientists. Many of them are recognized as leaders in their field. These world-class researchers are the most productive in Quebec. In addition, the full coordination of research components with the laboratory’s discipline guarantees synergies between clinicians and researchers, which enables rapid transfer of knowledge to care.
Information about IUCPQ:
Joël Clément, MA Communications
Assistants, talent and communication
Responsible for external communication and media relations
Quebec Cardiopulmonary Research Institute – Laval University
This news release may contain information about certain forward-looking statements as defined under applicable Canadian securities law. These include “believe,” “expect,” “plan,” “intention,” “will,” “should,” “expect,” “continue,” “estimate,” and “predict.” “And other similar expressions.In particular, this news release includes our APPRoAcH-2 trial, its Phase 2b COVID-19 clinical trials, and potential treatment of PAH and COVID-19 patients with apabetaron (and potentially other viruses), as well as cardiovascular disease and related comorbidity and other chronic diseases. Our actual results, events, or developments may differ materially from those expressed or implied by these forward-looking statements. We cannot guarantee that an event or expectation will occur or be fulfilled. By its very nature, forward-looking statements are subject to many assumptions and risk factors, including those described in the annual information form and the latest MD & A. These are incorporated by reference into this document and are available from SEDAR (www.sedar.com). The forward-looking statements contained in this news release have been explicitly modified by this notice and have been prepared as of the date of this document. We disclaim any intention to update or revise any forward-looking statement as a result of new information, future events, etc., and we are not obligated or liable, except as required by law.
For more information, please contact:
Investor public relations
Phone number: 403-254-9252
CBJ News Maker
The positive effects of apabetaron on pulmonary arterial hypertension were published in the American Journal of Respiratory and Critical Care Medicine, Canadian Business Journal.
Source link The positive effects of apabetaron on pulmonary arterial hypertension were published in the American Journal of Respiratory and Critical Care Medicine, Canadian Business Journal.